Senate brief
ADFC tells senate
it will hand out
fliers at Autzen
The ASUO Student Senate met
last night to approve appointments
and hear special requests from the
Asian/Pacific American Student
Union and the Asian Pacific
American Law Student Association.
The ASUO Program Finance
Committee announced they will
go over the Clark Document at
the ASUO Programs Council
meeting Nov. 7. University
President Dave Frohnmayer will
attend the meeting.
The Athletic Department
Finance Committee announced it
will work to inform students
about the ADFC ballot measure
in the upcoming special election.
Fliers will be handed out on the
footbridge near Autzen Stadium
on Saturday.
For appointments, two students
were approved to the ASUO
Elections Board.
Christina Diss’s appointment as
ASUO Elections Board publicity
coordinator was approved 16 to 1.
Stephanie Day’s appointment as
office manager was also approved
16 to 1.
The Senate also heard and
approved two special requests for
APASU and APULSA.
APASU requested a transfer of
$300 from their food holding
account for their fall reception
taking place Nov. 6. The request
was approved 16 to 1.
APULSA requested #984 from
the surplus to four members to a
law conference and competition.
Senate Ombudsman Andrew
Elliott suggested that senate give
#484 from surplus and #500 as a
loan to be repaid Dec. 1. The loan
would allow APULSA to approach
other funding sources for match
ing funds, but could still be paid
back with their fundraising budget
if they can’t match the funds.
APULSA members stated they
didn’t want to use their fundraising
budget because of future events
they have planned for this year.
The two motions to give APUL
SA $484 from the surplus, as well
as a $500 loan, passed 15 to 2.
An ASUO Executive open house
Oct. 24 was also announced. The
event will take place in the Ben
Linder Room and be open to
the public.
The Senate also announced that
the surplus for fall term — not
counting business done at the
meeting — is $11, 447.71.
— JanMontry
Candidates
continued from page 1
training and experience and knowl
edge that they need to be able to
compete in today’s society,”
Prozanski said.
Prozanski said he wouldn’t be op
posed to dedicated funding — per
haps a state sales tax, gross receipts
tax or added value tax — to help sta
bilize Oregon’s higher educational
system. Meanwhile, McNeill said
he’d like to model the state’s struc
ture based on Penn State University.
“The way they do it, they have
feeder schools,” McNeill said. “Most
people don’t go
to Penn State
for four years.
They go two
years to a satel
lite school and
then the re
maining two
(at) the main
campus. So I’d
kind of like to
turn what I call PfOZanskl
our satellite
schools, West
ern, Southern and Eastern, into
more satellite schools, which would
free up a lot of money to better UO
and OSU,
(and) also help
lower tuition.”
Gome Nov.
5, both candi
dates hope to
be victorious.
But more than
anything, both
hope voters fol
low their
hearts. McNeill
“Fm asking
voters to look
at the individuals that are running
and to their abilities and their expe
riences in life, and who is best
equipped to represent them in get
ting the job done,” Prozanski said.
A concurring McNeill:
“From the beginning I’ve said,
‘Yes I’m a Republican, but I’m more
of an Oregonian than anything,’” he
said. “When my opponent started
out, he started saying, ‘You need to
elect Democrats.’
“I’m saying, ‘No, you need to elect
the best person.’ And maybe he is
the best person, but I’d rather see
people choose one of us based on our
views and not based on our parties.”
Contact the senior news reporter
at bradschmidt@dailyemerald.com.
ipts of the
the candic
The full
Today and Friday the Emerald
will post its Q& A sessions
with the state’s two write-in
candidates for governor,
Richard Alevtzos and Gary
Alan Spanovich. Continue to
Breast cancer
continued from page 1
Better program with the Willamette
Valley Cancer Center. The program
provides wigs and cosmetics for
women who have had or are under
going chemotherapy. Cynthia’s Fine
Lingerie will provide prosthetics for
women who have had mastectomies.
In addition, Dochnahl said the
show will delineates preventative be
havior as well as offer current infor
mation on breast cancer.
“It is my belief that everyone will
learn something of value,” Dochnahl
said. She said preventative behavior
includes limited alcohol intake and
good nutrition and diet.
Risk increases with age, and
women older than 40 should have
yearly physicals and perform
monthly breast self-exams.
People whose family members
have developed the disease may also
be at an increased risk.
Eugene office AGS community
cancer control manager Kay
Hilsenkopf said women should check
carefully when doing a breast exam.
“It’s not just your breast — it’s a
whole area,” Hilsenkopf said. “Al
though we say to check your breast,
you also need to check the area
around that.”
She said that area is a square
shaped region that encompasses the
area beneath the collarbone, down
to the waist and under the arm.
“You can also get (a lump) under
your arm because that’s the closest
lymph node to your breast,” she said.
To assess one’s risk, Hilsenkopf
recommends visiting www.your
cancerrisk.harvard.edu or calling
(800)ACS-2345.
Informational pamphlets will also
be available at the fashion show.
In addition to learning about
the risks, attendees may also enjoy
the clothes modeled by students and
volunteers.
While designing her part of the
program, Skinner had a unique plan
for determining which retailers to
feature in the show.
“I took an informal poll of what
people wear on campus,” she said.
The retail stores who will be dis
playing their garments are Sweet
Potato Pie, Buffalo Exchange Ltd.,
Folkways, Greater Goods,
Recreational Equipment Inc. and
Emporium Department Store.
Organizers say they feel satis
fied with the show’s progress.
“It’s been a whirlwind of plan
ning, but I think it’s coming togeth
er very nicely,” Dochnahl said.
Contact the reporter
at ji!liandaley@dailyemerald.com.
Patriot
continued from page 1
The Patriot Act was passed by Con
gress a year ago in the wake of the
September 2001 terrorist attacks.
“The meeting will provide an op
portunity for students to learn how
the Patriot Act has decimated our
Bill of Rights and to clarify the signif
icance of this unconstitutional legis
lation,” said Nathaniel N-T, co-direc
tor of the University of Oregon
Survival Center, the event’s sponsor.
— Dave Goldberg
for the Emerald
Contraceptive Injection
medroxyprogesterone acetate injectable suspension
B>irtK corvtrol you-thirMc ae>ou-t jus-t 4xa year
DEPO-PROVERA Contraceptive Injection
(medroxyprogesterone acetate injectable suspension, USP)
This product is intended to prevent pregnancy. It does not protect against HIV
infection (AIDS) and other sexually transmitted diseases.
What is DEPO-PROVERA Contraceptive Injection?
DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an
intramuscular injection (a shot) in the buttock or upper arm once every 3 months (13 weeks). To
continue your contraceptive protection, you must return for your next injection promptly at the
end of 3 months (13 weeks), DEPO-PROVERA contains medroxyprogesterone acetate, a
chemical similar to (but not the same as) the natural hormone progesterone, which is produced
by your ovaries during the second half of your menstrual cycle. DEPO-PROVERA acts by
preventing your egg cells from ripening. If an egg is not released from the ovaries during your
menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA
also causes changes in the lining of your uterus that make it less likely for pregnancy to occur.
How effective Is DEPO-PROVERA Contraceptive Injection?
The efficacy of DEPO-PROVERA Contraceptive Injection depends on following the
recommended dosage schedule exactly (see "How often do I get my shot of DEPO-PROVERA
Contraceptive Injection?'). To make sure you are not pregnant when you first get
DEPO-PROVERA Contraceptive Injection, your first injection must be given ONLY during
the first 5 days of a normal menstrual period; ONLY within the first 5 days after childbirth if not
breast-feeding; and, if exclusively breast-feeding ONLY at the sixth week after childbirth. It is a
long-term injectable contraceptive when administered at 3-month (13-week) intervals.
DEPO-PROVERA Contraceptive Injection is over 99% effective, making it one of the most reliable
methods of birth control available. This means that the average annuaf pregnancy rate is less than
one for every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive
methods depends in part on how reliably each woman uses the method. The effectiveness of
DEPO-PROVERA depends only on the patient returning every 3 months (13 weeks) for her next
injection. Your health-care provider will help you compare DEPO-PROVERA with other
contraceptive methods and give you the information you need in order to decide which
contraceptive method is the nght choice for you.
The following table shows the percent of women who got pregnant while using different kinds of
contraceptive methods. It gives both the lowest expected rate of pregnancy ^he rate expected
in women who use each method exactly as it should be used) and the typical rate of pregnancy
(which includes women who became pregnant because they forgot to use their birth control or
because they did not follow the directions exactly).
Percent of Women Experiencing an Accidental Pregnancy
In the First Year of Continuous Use
DEPO-PROVERA
Implants (Norplant)
Female sterilization
Male stenlization
Oral contraceptive (pill)
Combined
Progestogen only
IUD
Progestasert
CopperT 380A
Condom (without spermicide)
Diaphragm (with spermicide)
Cervical cap
Withdrawal
Periodic abstinence
Spermicide alone
Vaginal Sponge
used before childbirth
used after childbirth
No method
Typical
Source: Trussell et at. Obstet Gynecol. 1990;76:558-567.
•From Norplant® package insert
Who should not use DEPO-PROVERA Contraceptive Injection?
Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you have
any of the following conditions:
• if you think you might be pregnant
• if you have any vaginal bleeding without a known reason
• if you have had cancer of the breast
• if you have had a stroke
■ if you have or have had blood clots (phlebitis) in your legs
• if you have problems with your liver or liver disease
• if you are allergic to DEPO-PROVERA (medroxyprogesterone acetate or any of its other
ingredients).
What other things should I consider before using DEPO-PROVERA
Contraceptive Injection?
You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is
important to tell your health-care provider if you have any of the following:
• a family history of breast cancer
• an abnormal mammogram (breast x-ray), fibrocystic breast disease, breast nodules or lumps, or
bleeding from your nipples
• kidney disease
• irregular or scanty menstrual periods
• high blood pressure
• migraine headaches
• asthma
• epilepsy (convulsions or seizures)
• diabetes or a family history of diabetes
• a history of depression
• if you are taking any prescnption or over-the-counter medications
This product Is Intended to prevent pregnancy. It does not protect against
transmission of HIV (AIDS) and other sexually transmitted diseases such as
chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
What if I want to become pregnant after using DEPO-PROVERA Contraceptive
Injection?
Because DEPO-PROVERA is a long-acting birth control method, it takes some time after your last
injection for its effect to wear off. Based on the results from a large study done in the United States,
for women who stop using DEPO-PROVERA in order to become pregnant it is expected that
about half of those who become pregnant will do so in about 10 months after their last injection;
about two thirds of those who become pregnant will do so in about 12 months; about 83% of
those who become pregnant will do so in about 15 months; and about 93% of those who become
pregnant will do so in about 18 months after their last injection. The length of time you use
DEPO-PROVERA has no effect on how long it takesyou to become preatant after you stop using it
What are the risks of using DEPO-PROVERA Contraceptive Injection?
I,Irregular Menstrual Bleeding
The side effect reported most frequently by women who use DEPO-PROVERA for
contraception is a change in their normal menstrual cycle. During the first year of using
DEPO-PROVERA, you might have one or more of the following changes; irregular or
unpredictable bleeding or spotting an increase or decrease in menstrual bleeding or no bleeding
at all. Unusually heavy or continuous bleeding however, is not a usual effect of DEPO-PROVERA
and if this happens, you should see your health-care provider right away. With continued use of
DEPO-PROVERA, Weeding usually decreases, and many women stop having periods completely.
In clinical studies of DEPO-PROVERA 55% of the women studied reported no menstrual
bleeding (amenorrhea) after I year of use, and 68% of the women studied reported no menstrual
bleeding after 2 years of use. The reason that your periods stop is because DEPO-PROVERA
causes a resting state in your ovaries. When your ovaries do not release an egg monthly, the
regular monthly growth of the lining of your uterus does not occur and, therefore, the bleeding
that comes with your normal menstruation does not take place. When you stop using
DEPO-PROVERA your menstrual period will usually, in time, return to its normal cycle.
2.8one Mineral Changes
Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral stored in
your bones. This could increase your risk of developing bone fractures. The rate of bone mineral
loss is greatest in the early years of DEPO-PROVERA use, but after that it begins to resemble the
normal rate of age-related bone mineral loss.
3. Cancer
Studies of women who have used different forms of contraception found that women who used
DEPO-PROVERA for contraception had no increased overall risk of developing cancer of the
breast, ovary, uterus, cervix, or liver However women under 35 years of age whose first exposure
to DEPO-PROVERA was within the previous 4 to 5 years may have a slightly increased risk of
developing breast cancer similar to that seen with oral contraceptives. You should discuss this with
your health-care provider.
4. Unexpected Pregnancy
Because DEPO-PROVERA is such an effective contraceptive method, the risk of accidental
pregnancy for women who get their shots regularly (every 3 months [13 weeks]) is very low.
While there have been reports of an increasedrisk of low birth weight and neonatal infant death
or other health problems in infants conceived close to the time of injection, such pregnancies are
uncommon. If you think you may have become pregnant while using DEPO-PROVERA for
contraception, see your health-care provider as soon as possible.
5Allergic Reactions
Some women using DEPO-PROVERA Contraceptive Injection have reported severe and
potentially life-threatening allergic reactions known as anaphylaxis and anaphylactoid reactions.
Symptoms include the sudden onset of hh«s or swelling and itching of the skin, breathing
difficulties, and a drop in blood pressure.
b.Other Risks
Women who use hormone-based contraceptives may have an increased nsk of blood dots or
stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin
to develop outside of the uterus (ectopic pregnancy). While these events are rare, you should
tell your health-care provider if you have any of the problems listed in the next section.
What symptoms may signal problems while using DEPO-PROVERA
Contraceptive Injection?
Call your health-care provider immediately if any of these problems occur following an injection
of DEPO-PROVERA:
• sharp chest pain, coughing up of blood, or sudden shortness of breath (indicating a possible clot
in the lung)
• sudden severe headache or vomiting, dizziness or fainting problems with your eyesight or
speech, weakness, or numbness in an arm or leg (indicating a possible stroke)
• severe pain or swelling in the calf (indicating a possible clot in the leg)
• unusually heavy vaginal bleeding
• severe pain or tenderness in the lower abdominal area
• persistent pain, pus, or bleeding at the injection site
What are the possible side effects of DEPO-PROVERA Contraceptive Injection?
I.Weight Gam
You may experience a weight gain while you are using DEPO-PROVERA. About two thirds of
the women who used DEPO-PROVERA in clinical trials reported a weight gain of about 5 pounds
during the first year of use. You may continue to gain weight after the first year Women in one
large study who used DEPO-PROvERA for 2 years gained an average total of 8.1 pounds over
those 2 years, or approximately 4 pounds per year. Women who continued for 4 years gained an
average total of 13.8 pounds over those 4 years, or approximately 3.5 pounds per year Women
who continued for 6 years gained an average total of 16.5 pounds over those 6 years, or
approximately 275 pounds per year
ZOther Side Effects
In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some
women reported the following effects that may or may not have been related to their use of
DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness, abdominal
cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps, nausea, vaginal
discharge or irritation, breast swelling and tenderness, bloating, swelling of the hands or feet,
backache, depression, insomnia, acne, pelvic pain, no hair growth or excessive hair loss, rash, hot
flashes, and joint pain. Other problems were reported by very few of the women in the clinical
trials, but some of these could be serious. These include convulsions, jaundice, urinary tract
infections, allergic reactions, fainting, paralysis, osteoporosis, lack of return to fertility, deep vein
thrombosis, pulmonary embolus, breast cancer or cervical cancer. If these or any other problems
occur during your use of DEPO-PROVERA, discuss them with your health-care provider.
Should any precautions be followed during use of DEPO-PROVERA
Contraceptive Injection?
1. Missed Periods
During the time you are using DEPO-PROVERA for contraception, you may skip a period, or your
periods may stop completely. If you have been receiving your DEPO-PROVERA injections
regularly every 3 months (13 weeks), then you are probably not pregnant However, if you think
that you may be pregnant, see your health-care provider
2. Laboratory Test Interactions
If you are scheduled for any laboratory tests, tell your health-care provider that you are using
DEPO-PROVERA for contraception. Certain blood tests are affected by hormones such as
DEPO-PROVERA.
3. Drug Interactions
Cytaoren (aminoglutethimide) is an anticancer drug that may significantly decrease the
effectiveness of DEPO-PROVERA if the two drugs are given during the same time
4. Nursine Mothers
Although DEPO-PROVERA can be passed to the nursing infant in the breast milk, no harmful
effects have been found in these children. DEPO-PROVERA does not prevent the breasts from
producing milk, so it can be used by nursing mothers. However to minimize the amount of
DEPO-PROVERA that is passed to the infant in the first weeks after birth, you should wait until
6 weeks after childbirth before you start using DEPO-PROVERA for contraception.
How often do I get my shot of DEPO-pROVERA Contraceptive Injection?
The recommended dose of DEPO-PROVERA is 150 mg every 3 months (13 weeks) given in a
single intramuscular injection in the buttock or upper arm. To make sure that you are not pregnant
at the time of the first injection, it is essential that the injection be given ONLY during the first
5 days of a normal menstrual period. If used following the delivery of a child, the first injection of
DEPO-PROVERA MUST be given within 5 days after childbirth if you are not breast-feeding or
6 weeks after childbirth if you are exclusively breast-feeding. If you wait longer than 3 months
(13 weeks) between injections, or longer than 6 weeks after delivery, your health-care provider
should determine that you are not pregnant before giving you your injection of DEPO-PROVERA.
Rx only CB-7-S
Pharmacia & Upjohn Company
Kalamazoo. Ml 49001, USA
Pharmacia
& Upjohn